Wearable defibrillator can prevent death in people with arrhythmias

Wearable cardioverter defibrillators are used by people who may be at higher risk for sudden cardiac arrest, including those with weakened heart function, awaiting cardiac transplant or with a condition that prevents or delays them from receiving an implanted defibrillator.

The device monitors heart rhythm, emits alarms if a serious arrhythmia occurs, delivers an electric shock to the heart if needed and alerts bystanders to help if the heart's electrical activity has stopped.

About 5,000 patients are using wearable defibrillators at any one time, usually for about 60 days, said Vincent N. Mosesso Jr., M.D., professor of emergency medicine at the University of Pittsburgh School of Medicine and principal investigator of the study.

“In these patients, the wearable defibrillator is a non-invasive 'insurance policy' against sudden arrest during their vulnerable period,” he said.

Researchers gathered heart rhythm records and calls about shocks from a registry of 14,475 patients with wearable defibrillators listed from 2007 through 2009. Of those, 185 (about 1 percent) received an appropriate shock and 91.6 percent survived one or more episodes of ventricular fibrillation or ventricular tachycardia, the most common abnormal rhythms during cardiac arrest.

Wearable defibrillators delivered 223 inappropriate shocks to 213 people who weren't experiencing ventricular fibrillation or ventricular tachycardia. However, no one died as a result. Researchers attribute the inappropriate shocks to signal noise, rapid non-VT rhythms, and rhythm misinterpretation.

Only about 7 percent of people in the United States who have sudden cardiac arrest outside the hospital survive to hospital discharge, and only about 21 percent who have them in the hospital survive to discharge.

“This study confirms the effectiveness of very early defibrillation as therapy for sudden cardiac arrest in high-risk patients when delivered by a wearable defibrillator,” Mosesso said. “These defibrillators provide patients the critical advantage of not having to wait for a bystander or emergency responder to recognize the cardiac arrest and use an automated external defibrillator or manual defibrillator — both of which can lead to delays in treatment and markedly worse survival rates.”

Co-authors are: Jie Li, M.S.; Douglas Landsittel, Ph.D. and Leonard I. Ganz, M.D. Author disclosures are on the abstract.

ZOLL LifeCor of Pittsburgh, which makes the wearable defibrillator used in the study, funded the research.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.